Zacks Analyst Blog Highlights: Cytori Therapeutics, Luminex Corp., Bank of NY Mellon, First Advantage Corporation and First American Corporation

Chicago, IL – June 30, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Cytori Therapeutics (CYTX - Analyst Report), Luminex Corp. (LMNX - Analyst Report), Bank of NY Mellon (BK - Snapshot Report), First Advantage Corporation (FADV - Analyst Report) and First American Corporation (FAF - Snapshot Report).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Monday’s Analyst Blog:

Cytori's IP and Cash Position Solid

Two concerns for investors in Cytori Therapeutics (CYTX - Analyst Report) have been the intellectual property (IP) and the cash position. We believe both are solid, and should not prohibit investment in the name at the current stock price.

Intellectual property has been a concern for investors ever since the summer of 2008 when the U.S. District Court in California removed The University of California from USPTO # 6,777,231, a patient licensed from Cal to Cytori which covers isolated adipose-derived stem cells. However, since that time, management has vigorously worked to protect its ability to isolate adipose-derived stem cells and sell the Celution System. And despite the loss of the '231 patent at Cal, Cytori has half a dozen other active patents protecting the Celution System, which includes 5 different device components or reagents.

Luminex - Expect Strong Growth in 2009

Luminex Corp. (LMNX - Analyst Report) posted revenue of $104.5 million in 2008, marking growth of 39% from 2007. Technology segment sales increased 34% to $83.6 million, while Assay segment sales grew 66% to $20.9 million. Through the first quarter 2009, Technology segment sales grew 13% to $21.1 million and Assay segment sales increased 2% to $4.5 million. Total revenue grew 11% in the first quarter to $25.6 million. Technology segment sales continue to be driven by growth in consumables and royalties.

EPS came in at $0.08 in 2008 and $0.04 (adjusted for litigation expense) in the first quarter 2009, compared to ($0.47) and ($0.03) in the year-earlier periods, respectively. Gross margins increased by 240 basis points in the most recent quarter as the company's product mix shifted towards higher margin consumables and royalties.

Expect Writedowns For Bank NY Mellon

Profits for 2009 at Bank of NY Mellon (BK - Snapshot Report) should reflect further writedowns from securitized mortgages that it still has on its books.

Presently, BK has securitized mortgages totaling $3­4 billion on its books, representing approximately 2% of the company's balance sheet.

Even though the company has seen the curtailment of its profits during this current crisis, it has posted profits and expects to remain profitable for 2009 overall.

First Advantage Receives Buyout Offer

Shares of First Advantage Corporation (FADV - Analyst Report) are trading higher today after the company received a buyout offer. First American Corporation (FAF - Snapshot Report), which already owns 74% of the outstanding shares of First Advantage, is seeking to acquire the remaining 26% of the company that it does not control.

The offer calls for First Advantage shareholders to receive 0.5375 shares of First American common stock for each share of First Advantage common stock owned. Based upon Friday's closing prices, the deal values First Advantage at $14.04 per share, for a premium of approximately 10%.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/ZacksInvestment

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com